Rigel stock dives on another drug study failure
August 13, 2014 at 14:49 PM EDT
Rigel Pharmaceuticals Inc.'s already-shortened list of potential drug treatments lost two more. An experimental treatment for dry eye disease, called R-348, failed a mid-stage trial, the South San Francisco company (NASDAQ: RIGL) said Wednesday...